Journal of Experimental & Clinical Cancer Research (Jun 2024)
Correction: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits
- Jiaojiao Hao,
- Wenhua Fan,
- Yizhuo Li,
- Ranran Tang,
- Chunfang Tian,
- Qian Yang,
- Tianhua Zhu,
- Chaoliang Diao,
- Sheng Hu,
- Manyu Chen,
- Ping Guo,
- Qian Long,
- Changlin Zhang,
- Ge Qin,
- Wendan Yu,
- Miao Chen,
- Liren Li,
- Lijun Qin,
- Jingshu Wang,
- Xiuping Zhang,
- Yandong Ren,
- Penghui Zhou,
- Lijuan Zou,
- Kui Jiang,
- Wei Guo,
- Wuguo Deng
Affiliations
- Jiaojiao Hao
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Wenhua Fan
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Yizhuo Li
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Ranran Tang
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University
- Chunfang Tian
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Qian Yang
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Tianhua Zhu
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Chaoliang Diao
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Sheng Hu
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Manyu Chen
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Ping Guo
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Qian Long
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Changlin Zhang
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Ge Qin
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Wendan Yu
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Miao Chen
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Liren Li
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Lijun Qin
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Jingshu Wang
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Xiuping Zhang
- Cloud Health Genomics Ltd
- Yandong Ren
- Cloud Health Genomics Ltd
- Penghui Zhou
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- Lijuan Zou
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Kui Jiang
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Wei Guo
- Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University
- Wuguo Deng
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Centre
- DOI
- https://doi.org/10.1186/s13046-024-03104-w
- Journal volume & issue
-
Vol. 43,
no. 1
pp. 1 – 5
Abstract
No abstracts available.